Supplement Documents

Financial results of the fiscal year 2014 (FY2014)

ended March 31, 2015.

Astellas Pharma Inc.

- Financial Results of FY2014
  - For the year ended March 31, 2015
  - Three months ended March 31, 2015
- Pipeline list

Cautionary statement regarding forward-looking information

This material includes forward-looking statements based on a number of assumptions and beliefs in light of the information currently available to management and subject to significant risks and uncertainties. Actual financial results may differ materially depending on a number of factors, including adverse economic conditions, currency exchange rate fluctuations, adverse legislative and regulatory developments, delays in new product launches, the pricing and product initiatives of competitors, the inability of the company to market existing and new product effectively, interruptions in production, infringement of the company's intellectual property rights and the adverse outcome of material litigation.

[For the year ended March 31, 2015]

1. Consolidated Results (Full Basis)

billion yen

	FY13 Full Year	FY14 Full Year	Change	Change (%)	Forecasts FY15 Full Year	Change from FY14 Change (%)
Sales	1,139.9	1,247.3	107.4	9.4%	1,362.0	9.2%
Cost of sales	330.6	333.2	2.6	0.8%		
Ratio to Sales	29.0%	26.7%				
Gross profit	809.3	914.1	104.8	12.9%		
SG&A expenses	397.0	452.5	55.5	14.0%		
Ratio to Sales	34.8%	36.3%				
Advertising and Sales Promotion	112.1	138.5	26.3	23.5%		
Personnel expenses	167.8	178.1	10.2	6.1%		
Other	117.0	136.0	18.9	16.2%		
R&D expenses	191.5	206.6	15.1	7.9%	229.0	10.8%
Ratio to Sales	16.8%	16.6%			16.8%	
Amortisation of intangible assets	36.0	38.7	2.7	7.4%		
Share of profits of associates and joint ventures	1.5	0.2	-1.2	-85.1%		
Other income	11.6	12.5	0.9	8.0%		
Gain on sales of property, plant and equipment	5.5	1.4	-4.1	-74.3%		
Other expense	81.0	43.3	-37.7	-46.5%		
Loss on sales and disposal of property, plant and equipment	4.1	1.2	-2.9	-70.2%		
Impairment losses	55.8	10.3	-45.5	-81.5%		
Restructuring costs	10.1	11.5	1.4	13.8%		
Net foreign exchange losses	8.0	3.6	-4.5	-55.5%		
Litigation costs	0.2	16.2	16.0	-		
Operating profit	116.8	185.7	68.9	59.0%	238.0	28.2%
Ratio to Sales	10.2%	14.9%			17.5%	
Finance income	6.8	7.1	0.3	4.0%		
Gain on sales of available-for-sale financial assets	5.0	5.1	0.1	2.0%		
Finance expense	1.7	3.1	1.4	85.6%		
Impairment losses for available-for-sale financial assets	1.2	2.6	1.4	124.2%		
Profit before tax	122.0	189.7	67.7	55.5%	239.0	26.0%
Ratio to Sales	10.7%	15.2%			17.5%	
Income tax expense	31.1	53.8	22.7	73.1%		
Profit for the year	90.9	135.9	45.0	49.5%	170.0	25.1%
Ratio to Sales	8.0%	10.9%			12.5%	
Comprehensive income	182.1	169.5	-12.6	-6.9%		

2. Consolidated Results (Core Basis)

billion yen

	FY13 Full Year	FY14 Full Year	Change	Change (%)	FY14 Revised Forecasts	Forecasts FY15 Full Year	Change from FY14 Change (%)
Sales	1,139.9	1,247.3	107.4	9.4%	1,210.0	1,362.0	9.2%
Cost of sales	330.6	333.2	2.6	0.8%			
Ratio to Sales	29.0%	26.7%					
Gross profit	809.3	914.1	104.8	12.9%			
SG&A expenses	397.0	452.5	55.5	14.0%			
Ratio to Sales	34.8%	36.3%					
Advertising and Sales Promotion	112.1	138.5	26.3	23.5%			
Personnel expenses	167.8	178.1	10.2	6.1%			
Other	117.0	136.0	18.9	16.2%			
R&D expenses	191.5	206.6	15.1	7.9%	200.0	229.0	10.8%
Ratio to Sales	16.8%	16.6%			16.5%	16.8%	
Amortisation of intangible assets	36.0	38.7	2.7	7.4%			
Share of profits of associates and joint ventures	1.5	0.2	-1.2	-85.1%			
Operating profit	186.3	216.5	30.2	16.2%	210.0	238.0	9.9%
Ratio to Sales	16.3%	17.4%			17.4%	17.5%	
Finance income	1.6	1.9	0.3	18.7%			
Finance expense	0.4	0.4	-0.0	-10.2%			
Profit before Tax	187.5	218.1	30.6	16.3%			
Ratio to Sales	16.4%	17.5%					
Income tax expense	54.7	64.8	10.1	18.6%			
Profit for the year	132.8	153.2	20.4	15.4%	154.0	170.0	10.9%
Ratio to Sales	11.6%	12.3%			12.7%	12.5%	

3. Exchange Rate

yen

	FY13 Ave.	FY14 Ave.	FY13 End	FY14 End	FY14 Revised Forecasts	Forecasts FY15 Full Year
USD/Yen	100	110	103	120	104	120
EUR/Yen	134	139	142	130	137	125

* Exchange rate fluctuations had positive impact by 47.7 billion yen on sales and positive impact by 18.0 billion yen on Core operating profit in FY2014

4. Reconciliation of Full Basis to Core Basis

Billion yen

	FY13			FY14		
Account item	Full basis	Adjustment	Core basis	Full basis	Adjustment	Core basis
Sales	**1,139.9**	**-**	**1,139.9**	**1,247.3**	**-**	**1,247.3**
Cost of sales	330.6	-	330.6	333.2	-	333.2
Gross profit	**809.3**	**-**	**809.3**	**914.1**	**-**	**914.1**
SG&A expenses	397.0	-	397.0	452.5	-	452.5
R&D expenses	191.5	-	191.5	206.6	-	206.6
Amortisation of intangible assets	36.0	-	36.0	38.7	-	38.7
Share of profits of associates and joint ventures	1.5	-	1.5	0.2	-	0.2
Other income *1	11.6	-11.6	-	12.5	-12.5	-
Other expense *1	81.0	-81.0	-	43.3	-43.3	-
Operating profit	**116.8**	**69.4**	**186.3**	**185.7**	**30.8**	**216.5**
Finance income *2	6.8	-5.2	1.6	7.1	-5.1	1.9
Finance expense *2	1.7	-1.2	0.4	3.1	-2.7	0.4
Profit before tax	**122.0**	**65.5**	**187.5**	**189.7**	**28.4**	**218.1**
Income tax expense	31.1	23.6	54.7	53.8	11.0	64.8
Profit for the year	**90.9**	**41.9**	**132.8**	**135.9**	**17.4**	**153.2**

*1. “Other income” and “Other expense” are excluded from Core results.
“Other income” and “Other expense” include gain/loss on sale and disposal of property, plant and equipment, impairment losses for other intangible assets, restructuring costs, litigation costs and net foreign exchange gains/losses, etc.

*2. Gain/loss on sale of available-for-sale (“AFS”) and impairment losses of AFS included in “Finance income” and “Finance expense” are excluded from Core results.

5. Segment Information by Region

billion yen

		FY13 Full Year	FY14 Full Year	Change	Change (%)	FY14 Revised Forecasts	Forecasts FY15 Full Year	Change from FY14 (%)
Sales		1,139.9	1,247.3	107.4	9.4%	1,210.0	1,362.0	9.2%
	Japan	530.6	498.7	-31.9	-6.0%	503.0	521.7	4.6%
	Ratio to Sales	46.5%	40.0%			41.6%	38.3%	
	Americas	287.0	361.0	74.0	25.8%	328.9	439.8	21.8%
	Ratio to Sales	25.2%	28.9%			27.2%	32.3%	
	Europe	264.3	313.3	49.0	18.6%	307.6	309.4	-1.3%
	Ratio to Sales	23.2%	25.1%			25.4%	22.7%	
	Asia and Oceania	58.0	74.2	16.2	28.0%	70.4	91.1	22.8%
	Ratio to Sales	5.1%	5.9%			5.8%	6.7%	

- Calculated according to locations of sellers.
- Europe: Including Middle East and Africa

6. Per Share Information

	FY13 Full Year	FY14 Full Year	FY14 Revised Forecasts	Forecasts FY15 Full Year
The number of shares issued (thousand) *	2,284,823	2,259,823		
Treasury Shares (thousand) *	53,681	66,681		
The number of shares issued after deducting Treasury Shares (thousand) *	2,231,141	2,193,141		
Earnings per share (Yen) *	40.45	61.50		77.51
Earnings per share (Yen) core base *	59.11	69.37	69.65	77.51
Dividend per share (Yen) *	27	30	30	32
Return on Equity (%)	7.4%	10.5%		
Dividend on Equity (%)	5.0%	5.1%		

* The company conducted a 5-for-1 stock split of common stock on April 1, 2014.
These figures are calculated on the assumption that the above stock split was implemented at the beginning of FY2013.

7. Addition to Property, Plant and Equipment Depreciation/Amortisation

billion yen

		FY13 Full Year	FY14 Full Year	Change	Change (%)	FY14 Revised Forecasts	Forecasts FY15 Full Year	Change from FY14 (%)
Addition to Property, Plant and Equipment								
	Consolidated	25.7	30.6	4.9	19.1%	31.0	35.0	14.4%
Depreciation(PP&E)								
	Consolidated	23.2	21.3	-1.9	-8.0%	23.0	22.5	5.5%
Amortisation(Intangible Assets) *								
	Consolidated	41.1	44.2	3.0	7.4%	43.0	53.0	20.0%

* Amortisation(Intangible Assets): Including amortisation of software, etc.

8. Sales of major products

1)Sales of global products

billion yen

	FY13 Full Year	FY14 Full Year	Change	Change (%)	billion yen FY14 Revised Forecasts	Forecasts FY15 Full Year	Change from FY14 Change (%)
Prograf	181.1	194.7	13.7	7.5%	187.5	192.6	-1.1%
Sales by Astellas	175.9	190.9	15.0	8.5%	184.0	190.1	-0.4%
Japan (Including Graceptor)	50.4	48.1	-2.3	-4.5%	48.6	49.9	3.7%
Americas	29.6	33.0	3.4	11.5%	32.5	32.4	-2.1%
Europe	70.8	77.7	6.9	9.7%	73.2	68.6	-11.7%
Advagraf	24.0	28.7	4.7	19.5%			
Asia and Oceania	25.0	32.0	7.0	28.0%	29.8	39.2	22.5%
Exports to third parties	5.2	3.8	-1.4	-26.2%	3.5	2.5	-33.9%
Harnal	59.5	56.0	-3.5	-5.9%	56.4	53.7	-4.1%
Sales by Astellas	55.2	51.9	-3.3	-6.0%	52.1	49.5	-4.6%
Japan	20.2	15.0	-5.2	-25.9%	14.9	12.9	-14.2%
Europe	19.4	18.0	-1.4	-7.2%	18.6	14.7	-18.0%
Asia and Oceania	14.9	18.3	3.4	22.6%	18.1	21.2	16.2%
Bulk and Royalties	4.3	4.1	-0.2	-4.9%	4.3	4.2	1.4%
Vesicare	133.8	135.2	1.4	1.0%	129.9	132.9	-1.7%
Japan	30.7	25.6	-5.1	-16.6%	26.9	26.4	3.2%
Americas	58.1	61.4	3.3	5.7%	55.7	63.8	3.9%
Europe	40.8	42.3	1.5	3.7%	41.7	36.0	-14.9%
Asia and Oceania	3.8	5.3	1.5	38.0%	5.1	6.3	18.1%
Betanis/Myrbetriq/Betmiga	28.2	53.1	25.0	88.6%	52.4	79.3	49.1%
Japan	11.6	14.8	3.2	27.5%	14.7	23.0	55.5%
Americas	14.5	27.9	13.4	92.0%	26.9	40.8	46.4%
Europe	2.1	10.3	8.2	398.8%	10.3	14.8	44.0%
Asia and Oceania	-	0.2	0.2	-	0.4	0.6	255.8%
Funguard/Mycamine	36.1	38.8	2.7	7.5%	38.1	40.6	4.6%
Japan	12.3	11.8	-0.5	-4.4%	11.9	12.2	3.5%
Americas	11.7	12.4	0.6	5.3%	11.3	12.3	-0.9%
Europe	8.6	10.2	1.6	19.0%	10.7	9.9	-3.0%
Asia and Oceania	3.4	4.4	1.0	29.6%	4.1	6.2	40.6%
Protopic	25.0	21.7	-3.3	-13.2%	19.7	13.7	-36.9%
Americas	11.7	10.3	-1.3	-11.5%	9.0	2.6	-75.1%
Europe	7.1	7.8	0.7	10.5%	7.5	6.6	-15.4%
Asia and Oceania	2.6	3.4	0.9	33.1%	3.1	4.3	25.4%
XTANDI	54.6	137.2	82.6	151.3%		229.4	67.2%
US	44.3	85.7	41.4	93.6%	71.8	141.6	65.3%
ex-US	10.3	51.5	41.2	398.2%		87.8	70.5%
Japan	-	14.9	14.9	-		23.0	54.7%
Americas (ex-US)	0.8	2.6	1.8	210.6%		4.2	58.1%
Europe	9.5	33.4	24.0	253.4%	31.5	58.8	75.8%
Asia and Oceania	0.0	0.6	0.6	-		1.9	212.8%
Eligard	18.3	19.0	0.6	3.5%		18.1	-4.6%
Europe	18.3	18.9	0.6	3.2%	19.6	17.9	-5.5%
Asia and Oceania	0.0	0.1	0.0	268.2%		0.2	256.0%

- Sales of products in Japan are shown in a gross sales basis.
- Europe: Including Middle East and Africa

2)Sales of products in Japan

billion yen

<Global products>	FY13 Full Year	FY14 Full Year	Change	Change (%)	billion yen FY14 Revised Forecasts	Forecasts FY15 Full Year	Change from FY14 Change (%)
Prograf （Including Graceptor）	50.4	48.1	-2.3	-4.5%	48.6	49.9	3.7%
Harnal	20.2	15.0	-5.2	-25.9%	14.9	12.9	-14.2%
Vesicare	30.7	25.6	-5.1	-16.6%	26.9	26.4	3.2%
Betanis	11.6	14.8	3.2	27.5%	14.7	23.0	55.5%
Funguard	12.3	11.8	-0.5	-4.4%	11.9	12.2	3.5%
XTANDI	-	14.9	14.9	-		23.0	54.7%
<Local products in Japan>							
Lipitor [Family]	62.4	46.9	-15.5	-24.8%	47.1	30.6	-34.7%
Caduet*	10.7	10.2	-0.5	-4.5%			
Micardis [Family]	97.6	95.7	-1.8	-1.9%	99.3	105.2	9.9%
Micombi	11.8	10.7	-1.1	-9.3%			
Micamlo	21.4	23.8	2.4	11.2%			
Gaster	25.7	18.0	-7.7	-30.1%	17.9	15.1	-16.3%
Myslee	28.2	19.4	-8.8	-31.3%	19.7	18.1	-6.4%
Seroquel	19.6	12.6	-7.1	-36.0%	12.6	10.6	-15.5%
Vaccines	35.0	38.8	3.9	11.1%	37.1	42.4	9.2%
Cefzon	6.4	5.1	-1.3	-19.8%	5.3	4.5	-11.6%
Celecox	44.3	41.8	-2.6	-5.8%	42.6	49.6	18.9%
Geninax	11.7	10.4	-1.4	-11.8%	12.0	10.4	0.4%
Bonoteo	14.1	13.0	-1.2	-8.2%	13.5	14.4	11.1%
Symbicort	35.6	33.0	-2.6	-7.4%	35.3	38.1	15.6%
Argamate	6.1	5.9	-0.1	-2.3%	5.9	6.4	8.1%
Kiklin	1.4	1.5	0.1	4.5%	1.8	2.2	46.1%
Gonax	2.5	3.4	0.9	33.5%	3.9	4.2	24.9%
Cimzia	3.2	5.0	1.8	55.2%	6.0	7.5	49.1%
Suglat	-	4.1	4.1	-		11.0	167.9%
Total Rx Sales In Japanese market	515.6	481.7	-33.8	-6.6%	487.0	507.0	5.2%

- Sales of products in Japan are shown in a gross sales basis.

*Transfer of Distribution for Caduet to Pfizer on April 1, 2015.

3)Sales of products in Americas and Europe

billion yen

	FY13 Full Year	FY14 Full Year	Change	Change (%)	billion yen FY14 Revised Forecasts	Forecasts FY15 Full Year	Change from FY14 Change (%)
Scan* (Americas)	61.8	66.3	4.5	7.2%	61.1	74.3	12.0%
Lexiscan	58.6	65.9	7.2	12.3%			
AmBisome (Americas)	8.1	9.0	0.9	11.7%	8.3	9.7	7.9%
Tarceva	44.7	48.9	4.1	9.3%			
(US)	28.9	33.5	4.7	16.2%			
(ex-US)	15.9	15.3	-0.5	-3.4%			
Qutenza (Europe)	1.4	1.9	0.4	31.6%			
DIFICLIR (Europe)	1.3	2.0	0.7	58.2%			

* Adenoscan + Lexiscan

4)Sales in Americas and Europe(Local currency)

Unit:M$

Americas	FY13 Full Year	FY14 Full Year	Change	Change (%)	FY14 Revised Forecasts	Forecasts FY15 Full Year	Change from FY14 Change (%)
Net Sales	2,863	3,284	421	14.7%	3,162	3,665	11.6%
Prograf	296	301	5	1.7%	312	270	-10.3%
Scan*	617	603	-14	-2.2%	587	619	2.6%
Lexiscan	585	599	14	2.4%			
AmBisome	80	82	2	1.9%	80	81	-1.1%
Protopic	116	94	-22	-19.3%	87	21	-77.2%
VESIcare	580	559	-21	-3.6%	536	532	-4.8%
Myrbetriq	145	254	109	75.1%	259	340	34.1%
MYCAMINE	117	112	-5	-4.0%	109	102	-9.2%
Tarceva	446	444	-2	-0.4%			
US	288	305	17	6.0%			
ex-US	158	139	-19	-12.0%			
XTANDI	450	803	353	78.5%		1,215	51.2%
US	441	779	338	76.5%	690	1,180	51.4%
Americas (ex-US)	8	24	15	183.2%		35	44.9%

* Adenoscan + Lexiscan

Unit:M€

Europe	FY13 Full Year	FY14 Full Year	Change	Change (%)	FY14 Revised Forecasts	Forecasts FY15 Full Year	Change from FY14 Change (%)
Net Sales	1,967	2,258	291	14.8%	2,246	2,475	9.6%
Harnal (Omnic)	176	159	-17	-9.7%	167	151	-5.0%
Sales by Astellas	144	130	-15	-10.1%	136	118	-9.0%
Capsule	69	63	-5	-7.8%	69	60	-4.7%
OCAS	75	66	-9	-12.3%	68	58	-13.1%
Bulk and Royalties	32	30	-3	-7.9%	31	33	12.5%
Prograf	565	588	23	4.0%	560	569	-3.1%
Sales by Astellas	527	560	33	6.3%	534	549	-2.0%
Advagraf	179	207	28	15.7%			
Exports to third parties	38	28	-10	-27.2%	26	20	-26.6%
Vesicare	303	305	1	0.4%	304	288	-5.5%
BETMIGA	15	74	59	383.0%	75	119	59.9%
Protopic	52	56	4	7.0%	55	53	-6.1%
MYCAMINE	64	74	10	15.3%	78	80	7.7%
Eligard	136	136	-0	-0.0%	143	143	4.9%
Qutenza	11	13	3	27.4%			
DIFICLIR	9	14	5	53.2%			
XTANDI	70	241	170	242.2%	230	470	95.2%

- Europe: Including Middle East and Africa

9.Consolidated statements of financial position

Billion yen

			31-Mar-14	31-Mar-15	
			Amount	Amount	Change
Assets			**1,653.1**	**1,793.6**	**140.5**
	Non-current assets		**739.8**	**827.6**	**87.8**
		Property, plant and equipment	191.5	202.9	11.4
		Goodwill	116.8	136.3	19.6
		Other intangible assets	280.1	295.8	15.7
		Trade and other receivables	―	15.6	15.6
		Investments in associates and joint ventures	1.8	2.0	0.2
		Deferred tax assets	45.5	51.2	5.7
		Other financial assets	95.0	110.1	15.1
		Other non-current assets	9.2	13.7	4.5
	Current assets		**913.3**	**966.0**	**52.7**
		Inventories	135.2	156.9	21.7
		Trade and other receivables	332.6	332.9	0.3
		Income tax receivable	2.7	6.9	4.2
		Other financial assets	35.4	59.9	24.5
		Other current assets	12.1	12.7	0.7
		Cash and cash equivalents	391.4	396.4	5.1
		Assets held for sale	3.9	0.1	-3.7

Billion yen

	31-Mar-14	31-Mar-15	
	Amount	Amount	Change
Equity and Liabilities	**1,653.1**	**1,793.6**	**140.5**
Equity	**1,268.5**	**1,317.9**	**49.4**
Equity attributable to owners of the parent	**1,268.5**	**1,317.9**	**49.4**
Share capital	103.0	103.0	-
Capital surplus	176.8	176.8	-
Treasury shares	-54.5	-87.0	-32.5
Retained earnings	864.8	905.1	40.3
Other components of equity	178.4	220.0	41.6
Liabilities	**384.6**	**475.7**	**91.0**
Non-current liabilities	**43.9**	**54.8**	**10.8**
Trade and other payables	0.1	0.1	0.0
Deferred tax liabilities	0.0	0.0	0.0
Retirement benefit liabilities	27.2	30.1	2.9
Provisions	4.3	4.8	0.6
Other financial liabilities	0.7	0.6	-0.1
Other non-current liabilities	11.7	19.1	7.5
Current liabilities	**340.7**	**420.9**	**80.2**
Trade and other payables	187.0	226.6	39.6
Income tax payable	13.2	14.1	0.9
Provisions	66.4	85.4	19.0
Other financial liabilities	1.1	1.3	0.3
Other current liabilities	73.0	93.4	20.5

10. Employee

Number of employees

	FY13 End	FY14 End
Total	17,649	17,113
Japan	8,082	7,241
Americas	2,883	2,975
Europe	4,580	4,628
Asia and Oceania	2,104	2,269
Total Medical Representatives	6,340	6,530

- Europe: Including Middle East and Africa

11. Shareholders

	FY13 End	FY14 End
Banks	29.2%	30.1%
Securities	4.4%	3.4%
Other companies	3.3%	3.4%
Foreign companies	53.4%	52.7%
Individuals and others	7.3%	7.6%
Treasury Stock	2.3%	3.0%

[Three months ended March 31, 2015]

1. Consolidated Results (Full Basis)

bilion yen

	FY14							
	APR.-JUN. (Quarterly)	Change (%)	JUL.-SEP. (Quarterly)	Change (%)	OCT.-DEC. (Quarterly)	Change (%)	JAN.-MAR. (Quarterly)	Change (%)
Sales	295.2	9.5%	299.3	9.0%	358.3	10.5%	294.5	8.4%
Cost of sales	76.0	-6.4%	83.1	4.5%	100.4	0.4%	73.7	5.4%
Ratio to Sales	25.7%		27.8%		28.0%		25.0%	
Gross profit	219.2	16.4%	216.2	10.8%	257.9	15.0%	220.8	9.5%
SG&A expenses	96.9	6.3%	104.9	12.3%	115.5	17.2%	135.3	18.7%
Ratio to Sales	32.8%		35.0%		32.2%		45.9%	
Advertising and Sales Promotion	28.2	15.1%	26.8	0.6%	38.1	32.4%	45.3	40.8%
Personnel expenses	42.4	3.0%	42.9	9.2%	44.5	5.0%	48.3	7.3%
Other	26.3	3.2%	35.1	28.1%	32.9	20.3%	41.6	13.1%
R&D expenses	47.6	8.0%	49.4	6.6%	51.0	5.9%	58.6	10.8%
Ratio to Sales	16.1%		16.5%		14.2%		19.9%	
Amortisation of intangible assets	8.9	0.8%	9.1	0.9%	10.1	11.1%	10.6	16.4%
Share of profits of associates and joint ventures	0.2	-1.6%	0.3	-65.6%	-0.4	-263.7%	0.1	69.5%
Other income	2.7	-	2.9	470.8%	1.0	518.2%	14.8	36.9%
Gain on sales of property, plant and equipment	0.0	27.9%	1.4	-	0.0	-64.8%	0.0	-99.8%
Net foreign exchange gains	2.5	-	-	-	-	-	6.4	-
Other expense	18.1	-0.6%	3.5	-66.8%	23.5	18.8%	7.1	-78.2%
Loss on sales and disposal of property, plant and equipment	0.2	20.2%	0.4	406.3%	0.2	-26.6%	0.5	-86.0%
Impairment losses	8.1	-30.3%	0.3	-95.8%	0.8	-94.8%	1.2	-94.8%
Restructuring costs	9.3	99.5%	2.0	-28.8%	0.2	-89.1%	-	-
Net foreign exchange losses	-	-	0.7	-19.2%	11.7	464.9%	-	-
Litigation costs	0.5	-	0.0	-90.9%	10.5	-	5.3	-
Operating profit	50.6	91.5%	52.6	40.9%	58.5	19.1%	24.0	510.2%
Ratio to Sales	17.1%		17.6%		16.3%		8.1%	
Finance income	1.8	183.5%	0.4	-70.7%	0.6	-57.0%	4.2	29.4%
Gain on sales of available-for-sale financial assets	0.9	-	0.2	-85.1%	0.1	-94.3%	4.1	40.7%
Finance expense	2.1	213.3%	0.7	898.8%	0.1	-42.8%	0.1	-78.0%
Impairment losses for available-for-sale financial assets	2.0	220.1%	0.6	-	-	-	0.0	-95.6%
Profit before tax	50.3	90.6%	52.4	35.0%	58.9	17.3%	28.1	329.3%
Ratio to Sales	17.0%		17.5%		16.5%		9.5%	
Income tax expense	14.4	120.0%	18.3	39.8%	14.2	14.8%	7.0	-889.5%
Profit for the period	35.9	80.9%	34.1	32.6%	44.8	18.1%	21.1	184.6%
Ratio to Sales	12.1%		11.4%		12.5%		7.2%	
Comprehensive income	22.5	-59.8%	65.3	112.8%	109.8	4.6%	-28.1	-191.9%

2. Consolidated Results (Core Basis)

bilion yen

	FY14							
	APR.-JUN. (Quarterly)	Change (%)	JUL.-SEP. (Quarterly)	Change (%)	OCT.-DEC. (Quarterly)	Change (%)	JAN.-MAR. (Quarterly)	Change (%)
Sales	295.2	9.5%	299.3	9.0%	358.3	10.5%	294.5	8.4%
Cost of sales	76.0	-6.4%	83.1	4.5%	100.4	0.4%	73.7	5.4%
Ratio to Sales	25.7%		27.8%		28.0%		25.0%	
Gross profit	219.2	16.4%	216.2	10.8%	257.9	15.0%	220.8	9.5%
SG&A expenses	96.9	6.3%	104.9	12.3%	115.5	17.2%	135.3	18.7%
Ratio to Sales	32.8%		35.0%		32.2%		45.9%	
Advertising and Sales Promotion	28.2	15.1%	26.8	0.6%	38.1	32.4%	45.3	40.8%
Personnel expenses	42.4	3.0%	42.9	9.2%	44.5	5.0%	48.3	7.3%
Other	26.3	3.2%	35.1	28.1%	32.9	20.3%	41.6	13.1%
R&D expenses	47.6	8.0%	49.4	6.6%	51.0	5.9%	58.6	10.8%
Ratio to Sales	16.1%		16.5%		14.2%		19.9%	
Amortisation of intangible assets	8.9	0.8%	9.1	0.9%	10.1	11.1%	10.6	16.4%
Share of profits of associates and joint ventures	0.2	-1.6%	0.3	-65.6%	-0.4	-263.7%	0.1	69.5%
Operating profit	66.0	48.2%	53.2	12.4%	81.0	17.8%	16.3	-36.5%
Ratio to Sales	22.4%		17.8%		22.6%		5.5%	
Finance income	1.0	55.6%	0.3	-1.2%	0.5	7.9%	0.2	-31.1%
Finance expense	0.1	112.4%	0.1	-8.3%	0.1	-24.0%	0.1	-35.8%
Profit before Tax	66.8	48.3%	53.4	12.4%	81.4	17.8%	16.4	-36.4%
Ratio to Sales	22.6%		17.8%		22.7%		5.6%	
Income tax expense	20.4	53.3%	18.8	16.4%	22.2	12.9%	3.4	-38.4%
Profit for the period	46.4	46.2%	34.6	10.4%	59.2	19.8%	13.0	-35.9%
Ratio to Sales	15.7%		11.6%		16.5%		4.4%	

3. Segment Information by Region

bilion yen

		FY14							
		APR.-JUN. (Quarterly)	Change (%)	JUL.-SEP. (Quarterly)	Change (%)	OCT.-DEC. (Quarterly)	Change (%)	JAN.-MAR. (Quarterly)	Change (%)
Sales		295.2	9.5%	299.3	9.0%	358.3	10.5%	294.5	8.4%
	Japan	112.8	-9.5%	124.4	-4.1%	151.4	-2.8%	110.1	-8.6%
	Ratio to Sales	38.2%		41.6%		42.2%		37.4%	
	Americas	83.8	21.9%	84.2	18.9%	100.3	29.1%	92.7	32.9%
	Ratio to Sales	28.4%		28.1%		28.0%		31.5%	
	Europe	82.4	32.9%	74.1	23.4%	86.8	15.0%	70.0	5.0%
	Ratio to Sales	27.9%		24.7%		24.2%		23.8%	
	Asia and Oceania	16.1	15.1%	16.7	19.0%	19.8	29.9%	21.7	46.8%
	Ratio to Sales	5.4%		5.6%		5.5%		7.4%	

- Calculated according to locations of sellers.
- Europe: Including Middle East and Africa

4. Addition to Property, Plant and Equipment
Depreciation/Amortisation

bilion yen

		FY14							
		APR.-JUN. (Quarterly)	Change (%)	JUL.-SEP. (Quarterly)	Change (%)	OCT.-DEC. (Quarterly)	Change (%)	JAN.-MAR. (Quarterly)	Change (%)
Addition to Property, Plant and Equipment									
	Consolidated	3.4	-31.6%	7.3	-21.4%	13.0	180.9%	6.9	0.8%
Depreciation(PP&E)									
	Consolidated	5.3	-7.1%	5.6	-0.8%	5.1	-14.7%	5.4	-9.0%
Amortisation(Intangible Assets) *									
	Consolidated	10.2	1.8%	10.4	1.7%	11.5	10.7%	12.0	14.9%

* Amortisation(Intangible Assets): Including amortisation of software, etc.

5. Sales of major products

1)Sales of global products

bilion yen

	FY14							
	APR.-JUN. (Quarterly)	Change (%)	JUL.-SEP. (Quarterly)	Change (%)	OCT.-DEC. (Quarterly)	Change (%)	JAN.-MAR. (Quarterly)	Change (%)
Prograf	47.0	6.6%	48.1	6.5%	52.6	9.7%	46.9	7.2%
Sales by Astellas	46.2	7.6%	47.3	8.0%	51.9	10.2%	45.6	8.2%
Japan (Including Graceptor)	11.4	-8.9%	12.2	-4.2%	13.6	-1.5%	10.8	-3.7%
Americas	8.8	22.1%	8.1	6.3%	8.7	3.4%	7.4	16.3%
Europe	18.6	9.2%	19.7	12.8%	21.0	14.3%	18.3	2.6%
Advagraf	6.6	18.8%	7.3	25.6%	7.8	23.6%	7.0	10.4%
Asia and Oceania	7.3	20.5%	7.2	22.5%	8.5	32.4%	9.0	35.2%
Exports to third parties	0.9	-29.2%	0.9	-39.1%	0.8	-15.7%	1.3	-18.1%
Harnal	13.7	-10.2%	13.7	-3.3%	15.5	-8.4%	13.1	-0.4%
Sales by Astellas	12.5	-10.2%	13.0	-1.1%	14.6	-6.8%	11.7	-5.2%
Japan	3.9	-24.3%	3.9	-25.5%	4.0	-29.0%	3.2	-24.3%
Europe	4.5	-10.5%	4.6	8.7%	5.7	-2.4%	3.2	-25.5%
Asia and Oceania	4.0	11.5%	4.4	25.0%	4.8	15.5%	5.1	39.1%
Bulk and Royalties	1.2	-9.6%	0.6	-33.8%	0.9	-27.7%	1.4	74.7%
Vesicare	33.0	4.4%	33.6	6.3%	37.6	1.1%	31.1	-7.2%
Japan	5.3	-25.0%	6.5	-5.9%	7.5	-8.9%	6.3	-25.6%
Americas	15.5	15.6%	15.0	6.2%	17.2	3.3%	13.6	-1.5%
Europe	11.0	8.3%	10.4	12.1%	11.5	2.5%	9.4	-7.3%
Asia and Oceania	1.2	22.6%	1.2	20.8%	1.4	37.8%	1.5	74.8%
Betanis/Myrbetriq/BETMIGA	10.7	128.2%	11.6	95.9%	15.4	82.7%	15.4	68.8%
Japan	2.7	12.2%	3.4	41.2%	4.4	37.7%	4.2	19.3%
Americas	6.2	187.3%	6.0	85.2%	7.7	72.3%	8.0	71.9%
Europe	1.8	-	2.2	679.9%	3.2	340.2%	3.1	240.0%
Asia and Oceania	0.0	-	0.0	-	0.1	-	0.1	-
Funguard/MYCAMINE	8.9	6.7%	9.6	3.5%	11.4	12.7%	8.9	6.5%
Japan	2.5	-10.2%	3.2	-0.7%	3.6	-3.2%	2.4	-4.7%
Americas	2.8	0.7%	2.8	-9.8%	3.5	13.1%	3.2	18.9%
Europe	2.7	34.0%	2.4	16.0%	3.1	30.2%	2.1	-4.2%
Asia and Oceania	0.9	21.1%	1.1	39.5%	1.1	32.7%	1.3	25.0%
Protopic	6.0	-1.2%	6.0	2.0%	5.9	-13.0%	3.7	-39.9%
Americas	3.1	8.6%	3.4	19.0%	3.2	-11.0%	0.7	-72.4%
Europe	2.1	29.5%	1.7	18.4%	1.9	6.9%	2.1	-6.1%
Asia and Oceania	0.8	14.1%	0.9	25.7%	0.9	61.0%	0.9	37.1%
XTANDI	23.4	174.6%	31.3	160.1%	40.3	147.9%	42.3	137.3%
US	14.7	80.4%	18.8	75.4%	25.8	104.4%	26.3	106.6%
ex-US	8.7	-	12.4	866.4%	14.5	299.8%	15.9	214.5%
Japan	1.5	-	4.1	-	4.6	-	4.7	-
Americas (ex-US)	0.4	-	0.5	322.9%	1.0	157.3%	0.7	110.4%
Europe	6.7	-	7.8	567.4%	8.7	168.6%	10.3	118.6%
Asia and Oceania	0.0	-	0.1	-	0.2	-	0.3	936.3%
Eligard	5.1	9.5%	4.4	3.8%	5.1	8.4%	4.4	-7.5%
Europe	5.1	9.4%	4.4	3.6%	5.1	8.2%	4.4	-8.0%
Asia and Oceania	0.0	-	0.0	-	0.0	130.9%	0.0	230.9%

- Sales of products in Japan are shown in a gross sales basis.
- Europe: Including Middle East and Africa

2)Sales of products in Japan

bilion yen

	FY14							
	APR.-JUN.	Change	JUL.-SEP.	Change	OCT.-DEC.	Change	JAN.-MAR.	Change
<Global products>	(Quarterly)	(%)	(Quarterly)	(%)	(Quarterly)	(%)	(Quarterly)	(%)
Prograf （Including Graceptor）	11.4	-8.9%	12.2	-4.2%	13.6	-1.5%	10.8	-3.7%
Harnal	3.9	-24.3%	3.9	-25.5%	4.0	-29.0%	3.2	-24.3%
Vesicare	5.3	-25.0%	6.5	-5.9%	7.5	-8.9%	6.3	-25.6%
Betanis	2.7	12.2%	3.4	41.2%	4.4	37.7%	4.2	19.3%
Funguard	2.5	-10.2%	3.2	-0.7%	3.6	-3.2%	2.4	-4.7%
XTANDI	1.5	-	4.1	-	4.6	-	4.7	-
<Local products in Japan>								
Lipitor [Family]	12.1	-22.8%	12.4	-24.3%	12.5	-28.3%	9.9	-23.3%
Caduet	2.6	-0.6%	2.6	-2.4%	2.8	-6.6%	2.3	-8.2%
Micardis [Family]	23.3	-1.6%	23.8	0.6%	28.0	-1.0%	20.6	-6.1%
Micombi	2.7	-6.8%	2.7	-7.0%	3.0	-9.8%	2.3	-13.8%
Micamlo	5.7	6.1%	5.8	21.8%	6.9	14.1%	5.5	3.4%
Gaster	4.8	-27.5%	4.7	-29.9%	4.7	-33.5%	3.8	-28.7%
Myslee	4.8	-30.8%	5.0	-32.2%	5.2	-30.8%	4.3	-31.5%
Seroquel	3.4	-34.7%	3.2	-37.5%	3.4	-36.4%	2.6	-35.2%
Vaccines	5.3	10.1%	7.3	26.6%	20.9	12.4%	5.3	-7.9%
Cefzon	1.2	-18.9%	1.3	-21.9%	1.4	-19.1%	1.1	-18.9%
Celecox	8.4	-15.7%	11.3	5.2%	12.0	2.9%	10.1	-15.7%
Geninax	2.3	-20.9%	2.0	-0.3%	3.8	-14.2%	2.2	-6.1%
Bonoteo	2.6	-14.9%	3.4	1.1%	3.7	-2.6%	3.2	-16.8%
Symbicort	6.2	-17.5%	8.3	8.3%	10.5	0.0%	8.0	-19.6%
Argamate	1.5	-3.8%	1.5	-3.5%	1.6	1.0%	1.4	-3.2%
Kiklin	0.3	14.7%	0.4	18.9%	0.4	6.8%	0.3	-16.5%
Gonax	0.8	63.9%	0.9	48.4%	1.0	26.7%	0.8	10.0%
Cimzia	1.1	95.4%	1.3	75.4%	1.4	48.8%	1.2	23.2%
Suglat	2.5	-	0.1	-	0.7	-	0.8	-
Total Rx Sales In Japanese market	109.0	-9.9%	120.5	-4.3%	145.8	-4.3%	106.4	-8.4%

- Sales of products in Japan are shown in a gross sales basis.

3)Sales of products in Americas and Europe

bilion yen

	FY14							
	APR.-JUN.	Change	JUL.-SEP.	Change	OCT.-DEC.	Change	JAN.-MAR.	Change
	(Quarterly)	(%)	(Quarterly)	(%)	(Quarterly)	(%)	(Quarterly)	(%)
Scan* (Americas)	16.6	-3.0%	15.6	-2.0%	17.1	13.8%	17.0	23.3%
Lexiscan	16.5	4.6%	15.6	6.0%	17.0	16.2%	16.8	24.1%
AmBisome (Americas)	1.9	-1.9%	2.3	5.0%	2.4	4.8%	2.5	45.3%
Tarceva	13.6	11.6%	11.2	4.0%	12.2	12.2%	11.9	8.9%
(US)	9.6	18.8%	7.6	9.2%	8.1	22.8%	8.2	14.2%
(ex-US)	3.9	-2.7%	3.6	-5.7%	4.1	-4.0%	3.7	-1.2%
Qutenza (Europe)	0.4	35.3%	0.4	31.2%	0.5	36.1%	0.5	24.4%
DIFICLIR (Europe)	0.5	92.9%	0.5	60.3%	0.5	44.3%	0.5	46.8%

* Adenoscan + Lexiscan

4)Sales in Americas and Europe(Local currency)

Unit:M$

	FY14							
	APR.-JUN.	Change	JUL.-SEP.	Change	OCT.-DEC.	Change	JAN.-MAR.	Change
Americas	(Quarterly)	(%)	(Quarterly)	(%)	(Quarterly)	(%)	(Quarterly)	(%)
Net Sales	821	17.8%	810	13.2%	880	13.7%	773	14.2%
Prograf	86	18.1%	78	1.1%	75	-9.9%	61	-1.4%
Scan*	163	-6.2%	150	-6.7%	149	-0.4%	142	6.3%
Lexiscan	161	1.1%	150	0.8%	148	1.7%	140	6.7%
AmBisome	19	-5.2%	22	0.1%	21	-8.0%	21	26.4%
Protopic	31	5.0%	32	13.3%	27	-22.8%	4	-84.8%
VESIcare	152	11.8%	145	1.0%	151	-9.5%	112	-17.0%
Myrbetriq	60	177.7%	58	76.2%	68	51.9%	67	48.3%
MYCAMINE	28	-2.7%	27	-14.2%	31	-0.1%	26	2.3%
Tarceva	133	7.9%	107	-1.2%	106	-2.4%	99	-7.0%
US	94	14.8%	73	3.7%	70	6.5%	68	-2.5%
ex-US	38	-6.0%	34	-10.3%	36	-15.9%	31	-15.7%
XTANDI	148	79.2%	187	70.0%	239	83.9%	230	80.0%
US	144	74.4%	181	67.2%	230	82.5%	224	80.0%
Americas (ex-US)	4	-	5	303.1%	9	131.3%	6	78.8%

* Adenoscan + Lexiscan

Unit:M€

	FY14							
	APR.-JUN.	Change	JUL.-SEP.	Change	OCT.-DEC.	Change	JAN.-MAR.	Change
Europe	(Quarterly)	(%)	(Quarterly)	(%)	(Quarterly)	(%)	(Quarterly)	(%)
Net Sales	589	22.3%	538	17.5%	608	9.5%	524	10.8%
Harnal (Omnic)	41	-17.4%	38	-3.8%	46	-11.2%	34	-3.2%
Sales by Astellas	32	-17.6%	33	3.5%	40	-7.0%	24	-19.6%
Capsule	16	-10.6%	17	13.1%	20	-12.6%	10	-19.0%
OCAS	16	-23.4%	17	-4.6%	19	-0.2%	14	-20.0%
Bulk and Royalties	9	-16.8%	5	-36.4%	6	-31.1%	10	86.5%
Prograf	139	-1.8%	149	3.9%	153	8.0%	146	6.1%
Sales by Astellas	133	0.5%	143	7.2%	147	9.3%	137	8.0%
Advagraf	47	9.4%	53	19.3%	55	18.0%	52	15.8%
Exports to third parties	6	-34.2%	6	-38.7%	5	-18.5%	9	-15.9%
Vesicare	78	-0.3%	76	6.8%	80	-2.3%	70	-2.0%
BETMIGA	13	-	16	638.2%	23	313.9%	23	244.8%
Protopic	15	19.2%	13	12.9%	13	1.8%	15	-2.8%
MYCAMINE	19	23.4%	18	10.4%	22	24.3%	15	1.8%
Eligard	36	0.7%	32	-1.3%	36	3.4%	33	-3.2%
Qutenza	3	24.5%	3	27.4%	4	30.8%	4	26.7%
DIFICLIR	3	77.6%	4	54.7%	4	38.1%	4	49.4%
XTANDI	48	-	56	530.6%	61	151.0%	76	120.5%

- Europe: Including Middle East and Africa

R&D Pipeline (As of May 2015)

1. Global Development

(1) Approved

*Compounds with "In-house" in this column include one discovered by collaborative research. (The same applicable hereafter.)

Code No. Generic Name	Product Name (Approval Date)	Classification	Target Disease	Area	Dosage Form	Licensor*	Remarks
erlotinib	Tarceva (Mar. 2015)	HER1/EGFR tyrosine kinase inhibitor	Pediatric ependymoma	US	Oral	In-house (co-development with Roche/Genentech)	The data was submitted to the FDA to fulfill Pediatric Written Request and the pediatric exclusivity was granted. Pediatric ependymoma is not a new indication.

(2) Phase-lll / Phase-ll (1/3)

Code No. Generic Name	Classification	Target Disease	Area / Phase	Dosage Form	Licensor	Remarks
MDV3100 enzalutamide	Androgen receptor inhibitor	Non-Metastatic castration-resistant prostate cancer, Prostate cancer in patients with non-metastatic biochemical recurrence	US/Europe/Asia Phase-III	Oral	Medivation	New indication
		Breast cancer	US/Europe Phase-II			New indication
		Hepatocellular carcinoma	US/Europe Phase-II			New indication

(2) Phase-lll / Phase-ll (2/3)

Code No. Generic Name	Classification	Target Disease	Area / Phase	Dosage Form	Licensor	Remarks
ASP0113 (VCL-CB01)	DNA vaccine for cytomegalovirus	Cytomegalovirus reactivation in hematopoietic cell transplant recipients	US/Europe/Japan Phase-III	Injection	Vical	
		Cytomegalovirus infection or reactivation in solid organ transplant recipients	US/Europe Phase-II			
YM905 solifenacin	Muscarine M_3 receptor antagonist	Neurogenic detrusor overactivity and idiopathic overactive bladder in pediatric patients	US/Europe Phase-III	Oral	In-house	New indication (pediatric)
EB178 solifenacin/ mirabegron	Concomitant use of solifenacin and mirabegron	Urinary frequency, urinary incontinence or urgency associated with overactive bladder	US/Europe/Asia Phase-III	Oral	In-house	
fidaxomicin	Macrocyclic antibiotic	Infectious enteritis (bacterial target: *Clostridium difficile*)	Japan Phase-III	Oral	Merck	
		Clostridium difficile infection in pediatric patients	Europe Phase-III			New indication (pediatric)
ASP015K	JAK inhibitor	Rheumatoid arthritis	Japan Phase-III US/Europe Phase-II	Oral	In-house	
ASP1517 (FG-4592) roxadustat	HIF stabilizer	Anemia associated with chronic kidney disease in patients not on dialysis and on dialysis	Europe Phase-III Japan Phase-II	Oral	FibroGen	

(2) Phase-lll / Phase-ll (3/3)

Code No. Generic Name	Classification	Target Disease	Area / Phase	Dosage Form	Licensor	Remarks
ASP2215	FLT3/AXL inhibitor	Acute myeloid leukemia	US/Europe/Japan/Asia Phase-III	Oral	In-house	
		Non-small cell lung cancer	US/Japan/Asia Phase-I			
YM311 (FG-2216)	HIF stabilizer	Renal anemia	Europe Phase-II Japan Phase-I	Oral	FibroGen	
ASKP1240	Anti-CD40 monoclonal antibody	Prevention of organ transplant rejection	US Phase-II Japan Phase-I	Injection	Kyowa Hakko Kirin	
ASP1707	GnRH antagonist	Endometriosis	Europe/Japan Phase-II	Oral	In-house	
		Prostate cancer	Europe Phase-I			
ASP8477	Inhibition of central sensitization	Neuropathic pain	Europe Phase-II	Oral	In-house	
ASP8232	VAP-1 inhibitor	Diabetic nephropathy	Europe Phase-II	Oral	In-house	
		Diabetic macular edema	US Phase-II			
ASP8273	Mutant-selective irreversible EGFR inhibitor	Non-small cell lung cancer	Japan/Asia Phase-II US Phase I	Oral	In-house	
ASP3662	11beta-HSD1 inhibitor	Painful diabetic peripheral neuropathy	US Phase-II	Oral	In-house	
		Alzheimer’s disease	US Phase-I			

2. Local Development: Japan

(1) Filed

Code No. Generic Name	Classification	Target Disease	Area / Phase	Dosage Form	Licensor	Remarks
ASP7374	Influenza vaccine	Prophylaxis of seasonal influenza	Japan Filed (May 2014)	Injection	UMN Pharma	
certolizumab pegol	PEGylated anti-tumor necrosis factor-alpha antibody	Disease modifying anti-rheumatic drugs (DMARD)-naive rheumatoid arthritis	Japan Filed (Jun. 2014)	Injection	UCB	New indication
YM060 ramosetron	5-HT3 receptor antagonist	Irritable bowel syndrome with diarrhea in female patients	Japan Filed (Jul. 2014)	Oral	In-house	New indication
ASP1585 (AMG 223) bixalomer	Amine-functional polymer	Hyperphosphatemia in patients not on dialysis with chronic kidney disease	Japan Filed (Mar. 2015)	Oral	Amgen	New indication
AMG 145 evolocumab	Anti-PCSK-9 monoclonal antibody	Hypercholesterolemia	Japan Filed (Mar. 2015)	Injection	Amgen (co-development with Amgen Astellas)	

(2) Phase-lll / Phase-ll

Code No. Generic Name	Classification	Target Disease	Area / Phase	Dosage Form	Licensor	Remarks
YM533 beraprost sodium	Prostacyclin receptor stimulator	Chronic renal failure (primary, nephrosclerosis)	Japan/Asia Phase-III	Oral	Toray	New indication
FK949E quetiapine	Serotonin/dopamine antagonist	Depressive episode in bipolar disorders	Japan Phase-III	Oral	AstraZeneca	New indication New formulation
ASP3550 degarelix	GnRH antagonist	Prostate cancer (three-month formulation)	Japan Phase-III	Injection	Ferring	New formulation
AMG 785 romosozumab	Anti-Sclerostin monoclonal antibody	Osteoporosis	Japan Phase-III	Injection	Amgen (co-development with Amgen Astellas)	
ASP0456 linaclotide	Guanylate cyclase type-C receptor agonist	Irritable bowel syndrome with constipation	Japan Phase-III	Oral	Ironwood	
		Chronic constipation	Japan Phase-II			
ASP1585 (AMG 223) bixalomer	Amine-functional polymer	Hyperphosphatemia in patients on dialysis with chronic kidney disease (granule formulation)	Japan Bioequivalence study	Oral	Amgen	New formulation
ASP7373	Influenza vaccine	Prophylaxis of H5N1 influenza	Japan Phase-II	Injection	UMN Pharma	
ASP1941 ipragliflozin	SGLT2 inhibitor	Type 1 diabetes mellitus	Japan Phase-II	Oral	In-house (co-development with Kotobuki)	New indication

3. Local Development: Europe

(1) Filed

Code No. Generic Name	Classification	Target Disease	Area / Phase	Dosage Form	Licensor	Remarks
NGX-4010 capsaicin	TRPV1 agonist	Peripheral neuropathic pain in diabetic patients	Europe Filed (Dec. 2014)	Patch	HealthCare Royalty Partners	New indication

4. Local Development: US

(1) Approved

Code No. Generic Name	Product Name (Approval Date)	Classification	Target Disease	Area	Dosage Form	Licensor	Remarks
isavuconazonium sulfate	CRESEMBA (Mar. 2015)	Azole antifungal	Treatment of invasive aspergillosis and invasive mucormycosis in patients 18 years of age and older	US	Injection Oral	Basilea	

(2) Phase-lll / Phase-ll

Code No. Generic Name	Classification	Target Disease	Area / Phase	Dosage Form	Licensor	Remarks
isavuconazonium sulfate	Azole antifungal	Candidemia / Invasive candidiasis	US Phase-III	Injection Oral	Basilea	New indication

5. Phase-I

Code No. Generic Name	Target Disease	Dosage Form	Licensor
AGS-16C3F	Cancer (ADC technology)	Injection	In-house (ADC technology in-licensed from Seattle Genetics)
ASG-22ME	Cancer (ADC technology)	Injection	In-house (co-development with Seattle Genetics)
ASG-15ME	Cancer (ADC technology)	Injection	In-house (co-development with Seattle Genetics)
CK-2127107	Skeletal muscle disease	Oral	Cytokinetics
ASP5878	Cancer	Oral	In-house
ASP7962	Osteoarthritis, Chronic low back pain	Oral	In-house
YM178 mirabegron	Neurogenic detrusor overactivity and idiopathic overactive bladder in pediatric patients	Oral	In-house
AGS67E	Cancer (ADC technology)	Injection	In-house (ADC technology in-licensed from Seattle Genetics)
ASP5633	Stress urinary incontinence	Oral	In-house
ASP2205	Stress urinary incontinence	Oral	In-house
ASP5094	Rheumatoid arthritis	Injection	In-house
ASP6858	Chronic kidney disease	Oral	In-house
AMG 103 blinatumomab	Acute lymphoblastic leukemia	Injection	Amgen (co-development with Amgen Astellas)
ASP4132	Cancer	Oral	In-house
ASP4345	Cognitive impairment associated with schizophrenia	Oral	In-house
ASP6282	Underactive bladder	Oral	In-house

6. Project Discontinued / Removal from Pipeline List

(1) Filed / Phase-II

Code No. Generic Name	Target Disease	Area / Phase	Reason
nateglinide	Type 2 diabetes Combination with DPP-4 inhibitor	Japan Filed (Jul. 2014)	Withdrew the NDA for strategic reasons and discontinued the development.
AMG 102 rilotumumab	Gastric cancer	Japan Phase-III	Discontinued the development following study termination.
ASP7991	Secondary hyperparathyroidism	Japan Phase-II	Discontinued the development based on Phase-II study results.

(2) Phase-I

Code No. Generic Name	Target Disease
ASP3325	Hyperphosphatemia
ASP3700	Osteoarthritis
ASP9226	Neuropathic pain
ASP7657	Diabetic nephropathy

(3) Removal from Pipeline List

Code No. Generic Name	Target Disease	Area / Phase	Remarks
AMG 337	Gastric cancer	Japan Phase-II	Removed from the pipeline list for strategic reasons based on discussion with Amgen.

<Changes from the Previous Announcement on February 2, 2015> (Changed underlined items)

Launched

-Enzalutamide: Removed the following description.

-Nitisinone: Removed the following description.

Code No. Generic Name	Product Name (Approval Date)	Classification	Target Disease	Area	Dosage Form	Licensor	Remarks
MDV3100 enzalutamide	XTANDI (Dec. 2014)	Androgen receptor inhibitor	Metastatic castration-resistant prostate cancer in adult men who are asymptomatic or mildly symptomatic after failure of androgen-deprivation therapy in whom chemotherapy is not yet clinically indicated	Europe	Oral	Medivation	New indication
nitisinone	Orfadin (Dec. 2014)	4-Hydroxyphenyl pyruvate dioxygenase inhibitor	Hereditary tyrosinemia type 1	Japan	oral	Sobi	

Pediatric exclusivity granted

-Erlotinib: Pediatric exclusivity granted.

Code No. Generic Name	Product Name (Approval Date)	Classification	Target Disease	Area	Dosage Form	Licensor	Remarks
erlotinib	Tarceva (Mar. 2015)	HER1/EGFR tyrosine kinase inhibitor	Pediatric ependymoma	US	Oral	In-house (co-development with Roche/ Genentech)	The data was submitted to the FDA to fulfill Pediatric Written Request and the pediatric exclusivity was granted. Pediatric ependymoma is not a new indication.

Approved

-Isavuconazonium sulfate: Approved in US in March 2015.

Code No. Generic Name	Product Name (Approval Date)	Classification	Target Disease	Area	Dosage Form	Licensor	Remarks
isavuconazonium sulfate	CRESEMBA (Mar. 2015)	Azole antifungal	Treatment of invasive aspergillosis and invasive mucormycosis in patients 18 years of age and older	US	Injection Oral	Basilea	

Filed

-Bixalomer: Filed in Japan in March 2015.

-Evolocumab: Filed in Japan in March 2015.

Code No. Generic Name	Classification	Target Disease	Area / Phase	Dosage Form	Licensor	Remarks
ASP1585 (AMG 223) bixalomer	Amine-functional polymer	Hyperphosphatemia in patients not on dialysis with chronic kidney disease	Japan Filed (Mar. 2015)	Oral	Amgen	New indication
AMG 145 evolocumab	PCSK9 inhibitor	Hypercholesterolemia	Japan Filed (Mar. 2015)	Injection	Amgen (co-development with Amgen Astellas)	

Phase-III / Phase-II

-Enzalutamide: Entered into Phase-II in hepatocellular carcinoma.

Code No. Generic Name	Classification	Target Disease	Area / Phase	Dosage Form	Licensor	Remarks
MDV3100	Androgen receptor inhibitor	Hepatocellular carcinoma	US/Europe Phase-II	Oral	Medivation	New indication

-ASP2215: Entered into Phase-III in acute myeloid leukemia and Phase-I in non-small cell lung cancer.

-ASP8273: Added the description of Asia.

-ASP3662: Entered into Phase-II.

-Ipragliflozin: Entered into Phase-II.

Code No. Generic Name	Classification	Target Disease	Area / Phase	Dosage Form	Licensor	Remarks
ASP2215	FLT3/AXL inhibitor	Acute myeloid leukemia	US/Europe/ Japan/Asia Phase-III	Oral	In-house	
		Non-small cell lung cancer	US/Japan/Asia Phase-I			
ASP8273	Mutant-selective irreversible EGFR inhibitor	Non-small cell lung cancer	Japan/Asia Phase-II US Phase I	Oral	In-house	
ASP3662	11beta-HSD1 inhibitor	Painful diabetic peripheral neuropathy	US Phase-II	Oral	In-house	
ASP1941 ipragliflozin	SGLT2 inhibitor	Type 1 diabetes mellitus	Japan Phase-II	Oral	In-house (co-development with Kotobuki)	New indication

Phase-I

-Blinatumomab [Acute lymphoblastic leukemia]: Entered into Phase-I.

-ASP4132 [Cancer]: Entered into Phase-I.

-ASP4345 [Cognitive impairment associated with schizophrenia]: Entered into Phase-I.

-ASP6282 [Underactive bladder]: Entered into Phase-I.

Project Discontinued / Removal from Pipeline List

-Nateglinide [Type 2 diabetes, combination with DPP-4 inhibitor]: Withdrew the NDA in Japan.

-Rilotumumab [Gastric cancer] in Phase-III in Japan: Discontinued the development.

-ASP7991 [Secondary hyperparathyroidism] in Phase-II in Japan: Discontinued the development.

-ASP3325 [Hyperphosphatemia] in Phase-I: Discontinued the development.

-ASP3700 [Osteoarthritis] in Phase-I: Discontinued the development.

-ASP9226 [Neuropathic pain] in Phase-I: Discontinued the development.

-ASP7657 [Diabetic nephropathy] in Phase-I: Discontinued the development.

-AMG 337 [Gastric cancer] in Phase-II in Japan: Removed from the pipeline list.